What the research found

Lung cancer affects roughly one in seven cases among people who have never smoked—a population often overlooked in screening guidelines. In the United States, never-smokers develop lung cancer at rates comparable to other common cancers like myeloma or thyroid cancer. The disease burden is particularly concentrated in women, especially those of Asian or Hispanic descent, where over half of diagnosed cases occur in never-smokers.

Current screening recommendations from major health organisations target smokers and recent ex-smokers, based on evidence from large trials like NLST and NELSON. However, these organisations have not formally evaluated screening effectiveness in never-smokers through comparable trials. The available evidence on screening benefit in never-smokers comes largely from observational studies, mostly conducted in East Asian populations where baseline lung cancer risk differs from Western populations.

Why it matters for you

If you've never smoked and are thinking about your cancer risk profile, this matters because screening guidelines are not yet personalised to your situation. Standard recommendations don't apply to you, yet your absolute risk depends on factors like age, sex, ancestry, and exposure history—not smoking status alone. For younger adults or those with family history of lung cancer, understanding this gap is relevant to your preventive strategy.

The challenge is that good data on screening benefit specifically in Western never-smokers doesn't exist yet. This means discussions about screening with your clinician can't rely on the same level of evidence that supports screening in smokers. You'd be making a more individual risk-benefit calculation, which requires clarity about your personal risk factors and the limitations of available screening trials.

Caveats

• No randomised controlled trials of screening have been conducted in never-smokers living in Western countries
• Available studies are predominantly observational, limiting causal inference about screening benefit
• Most existing data comes from East Asian populations, where lung cancer drivers and baseline risk may differ meaningfully from Western populations
• Current guidelines reflect population-level analysis rather than individualised risk assessment